BEGIN:VCALENDAR VERSION:2.0 PRODID:-//www.twentythree.net, see addthisevent.com for calendar stuff though//EN BEGIN:VEVENT DTSTAMP:20260616T120000Z STATUS:CONFIRMED DTSTART:20260616T080000Z DTEND:20260616T120000Z SUMMARY:Innovations and Emerging Tools in Peptide Science DESCRIPTION:https://events.bitesizebio.com/innovations-and-emerging-tools-in \n\nDiscover how today’s advanced peptide technologies are shaping \ntomorrow’s research, development, and manufacturing success.\n\n \n\n*In this symposium, you'll learn about:*\n\n-\n\nScalable peptide API manufacturing and purification expertise for \nGLP‑1 class molecules\n\n-\n\nLabel‑free, real‑time cell‑based bioassays for peptide activity, \noptimization, and safety testing\n\n-\n\nNon‑destructive Raman raw material identification through opaque \ncontainers to streamline GMP workflows\n\n-\n\nInert LC/MS strategies for enhanced peptide separation, impurity \nprofiling, and molecular weight confirmation\n\n \n\nThis digital symposium explores the innovations shaping the future of \npeptide‑driven science, featuring modern analytical tools across cell \nanalysis, chemistries, spectroscopy, and mass spectrometry. Experts \nwill reveal practical approaches for integrating these technologies to \nstrengthen and streamline peptide analysis.\n\n \n\nAttendees will gain a clear view of emerging technologies and \npractical strategies across modern research and applied science. Join \nthe symposium to discover how to connect these advances directly to \nyour own work.\n\n \n\n10:00 - 10:05 - Intro\n\n_Vitan Blagotinsek, Agilent Technologies_\n\n \n\n10:05 - 10:20 - Highlight Talk - *Scaling the GLP-1 Surge: Peptide API \nDevelopment, Purification and Manufacturing at AAT*\n\n_Wolfgang Schiek, BioVectra_\n\n \n\nAs the paradigm shift in diabetes management and the surge in \nanti-obesity drug sales and development are propelling unprecedented \ndemand for complex peptide APIs therapies, reliable high quality \npeptide API manufacturing and purification are critical. Agilent \nAdvanced Therapeutics provides specialized expertise and scaling \ncapacity for these GLP-1 Agonists. We support our customers from \npreclinical to commercial through swift, customer-focused \nimplementation in state-of-the-art facilities and are continuously \nexpanding capabilities, true to our commitment: Invested in Science, \nInvested in You!\n\n \n\n10:20 - 11:05 - Talk 1: *Accelerating Synthetic Peptide Discovery, \nQuality Control, and Safety Testing with xCELLigence Bioassay*\n\n_Leyna Zhao, Agilent Technologies_\n\n \n\nSynthetic peptides and proteins are rapidly emerging as important \ntherapeutic modalities, driving the need for robust approaches to \nevaluate biological activity, product quality, and safety throughout \ndevelopment. In this webinar, we will explore how Agilent’s label free \nxCELLigence Real Time Cell Analysis (RTCA) platforms can support \nsynthetic peptide discovery, quality evaluation, and safety testing \nthrough functional, cell based bioassays. Selected case studies will \nhighlight the use of real time, kinetic cellular readouts in peptide \ndiscovery and optimization workflows. Evaluation criteria for \nbiological products will be reviewed in the context of ICH Q6B \nspecifications, with emphasis on the role of bioassays in assessing \nbiological activity. In addition, examples of toxicity testing using \nxCELLigence RTCA—including published vaccine related applications—will \ndemonstrate how real time cell based assays can provide sensitive and \nreproducible QC results.\n\n \n\n11:10 - 11:50 - Talk 2: *Unlocking Deeper Insights into Peptide Purity \nand Impurity Profiling with LC/MS for GLP-1 RA Characterization*\n\n_Holger Stalz, Agilent Technologies_\n\n \n\nSynthetic Peptide therapeutics are reshaping the biopharma landscape, \nand GLP-1 receptor agonists are at the center of that momentum—raising \nthe stakes for purity assessment and impurity profiling. Join this \nwebinar to see how Agilent’s advanced LC/MS workflows help scientists \ntackle these challenges with greater confidence and efficiency. You’ll \nlearn how the InfinityLab Pro iQ Plus LC/MSD enables reliable peptide \npurity confirmation, while the Agilent BioQTOF high-resolution \nLC/MS/MS system supports detailed sequence confirmation and impurity \nidentification. We’ll also show how OpenLab CDS and MassHunter \nBioConfirm software simplify complex data interpretation, helping QC \nand R&D teams move faster and make more confident decisions in peptide \ncharacterization.\n\n \n\n11:55 - 12:35 - Talk 3: *Raman Spectroscopy in Peptide Pharmaceuticals\n*\n\n_Jan Wuelken, Agilent Technologies_\n\n \n\nRapid, non destructive raw material identification (RMID) through all \ntypes of packaging. Reliable identity verification of peptides, amino \nacids, protected building blocks, and excipients is a critical step in \npeptide manufacturing. The Agilent Vaya Raman Raw Material Identity \nVerification System is specifically designed to identify raw materials \ndirectly through non transparent and opaque containers, without \nopening the package. By leveraging Spatially Offset Raman Spectroscopy \n(SORS), Vaya minimizes interference from container walls, liners, and \nfluorescence. This enables fast and reliable identification through \ntypical peptide pharma packaging, including plastic drums, paper and \nmulti layer bags, FIBCs, and amber glass containers. The through \ncontainer measurement capability eliminates the need for sampling, \nsignificantly reducing the risk of cross contamination and protecting \noperators from hazardous, highly potent, or sterile materials. At the \nsame time, it streamlines workflows by reducing handling steps and \noperator exposure. Agilent Vaya supports high throughput, GMP \ncompliant raw material testing, accelerates release to manufacturing, \nand helps ensure a secure, efficient supply of materials for peptide \nsynthesis and downstream processing—from early development to \ncommercial production.\n\n \n\n12:40 - 13:15 - Talk 4: *Advanced Column Solutions to enhance your \nPeptide Analysis and Purification Workflows*\n\n_Katrien Sabbe, Agilent Technologies_\n\n \n\nWhether you're optimizing existing methods or developing new ones, \nthis session will equip you with the tools to streamline your peptide \ncharacterization and purification. LC analysis of peptides can be \nchallenging due to their sensitivity to metal interactions within \nchromatographic systems, often leading to poor peak shape and reduced \nsensitivity. Agilent Altura HPLC columns with Ultra Inert technology \novercome these challenges by minimizing metal-analyte interactions. We \nwill illustrate how this innovation enhances resolution, \nreproducibility, and quantification in reversed phase and HILIC \nseparations of therapeutic peptides such as GLP-1 receptor agonists. \nFurthermore we will explore preparative techniques and purification \nworkflows, offering tips for achieving high purity and recovery in \nsynthetic peptide purification. X-ALT-DESC;FMTTYPE=text/html:

Innovations and Emerging Tools in Peptide Science

Discover how today’s advanced peptide technologies are shaping tomorrow’s research, development, and manufacturing success.

 

In this symposium, you'll learn about:

 

This digital symposium explores the innovations shaping the future of peptide‑driven science, featuring modern analytical tools across cell analysis, chemistries, spectroscopy, and mass spectrometry. Experts will reveal practical approaches for integrating these technologies to strengthen and streamline peptide analysis.

 

Attendees will gain a clear view of emerging technologies and practical strategies across modern research and applied science. Join the symposium to discover how to connect these advances directly to your own work.

 

10:00 - 10:05 - Intro

Vitan Blagotinsek, Agilent Technologies

 

10:05 - 10:20 - Highlight Talk - Scaling the GLP-1 Surge: Peptide API Development, Purification and Manufacturing at AAT

Wolfgang Schiek, BioVectra

 

As the paradigm shift in diabetes management and the surge in anti-obesity drug sales and development are propelling unprecedented demand for complex peptide APIs therapies, reliable high quality peptide API manufacturing and purification are critical. Agilent Advanced Therapeutics provides specialized expertise and scaling capacity for these GLP-1 Agonists. We support our customers from preclinical to commercial through swift, customer-focused implementation in state-of-the-art facilities and are continuously expanding capabilities, true to our commitment: Invested in Science, Invested in You!

 

10:20 - 11:05 - Talk 1: Accelerating Synthetic Peptide Discovery, Quality Control, and Safety Testing with xCELLigence Bioassay

Leyna Zhao, Agilent Technologies

 

Synthetic peptides and proteins are rapidly emerging as important therapeutic modalities, driving the need for robust approaches to evaluate biological activity, product quality, and safety throughout development. In this webinar, we will explore how Agilent’s label free xCELLigence Real Time Cell Analysis (RTCA) platforms can support synthetic peptide discovery, quality evaluation, and safety testing through functional, cell based bioassays. Selected case studies will highlight the use of real time, kinetic cellular readouts in peptide discovery and optimization workflows. Evaluation criteria for biological products will be reviewed in the context of ICH Q6B specifications, with emphasis on the role of bioassays in assessing biological activity. In addition, examples of toxicity testing using xCELLigence RTCA—including published vaccine related applications—will demonstrate how real time cell based assays can provide sensitive and reproducible QC results.

 

11:10 - 11:50 - Talk 2: Unlocking Deeper Insights into Peptide Purity and Impurity Profiling with LC/MS for GLP-1 RA Characterization

Holger Stalz, Agilent Technologies

 

Synthetic Peptide therapeutics are reshaping the biopharma landscape, and GLP-1 receptor agonists are at the center of that momentum—raising the stakes for purity assessment and impurity profiling. Join this webinar to see how Agilent’s advanced LC/MS workflows help scientists tackle these challenges with greater confidence and efficiency. You’ll learn how the InfinityLab Pro iQ Plus LC/MSD enables reliable peptide purity confirmation, while the Agilent BioQTOF high-resolution LC/MS/MS system supports detailed sequence confirmation and impurity identification. We’ll also show how OpenLab CDS and MassHunter BioConfirm software simplify complex data interpretation, helping QC and R&D teams move faster and make more confident decisions in peptide characterization.

 

11:55 - 12:35 - Talk 3: Raman Spectroscopy in Peptide Pharmaceuticals

Jan Wuelken, Agilent Technologies

 

Rapid, non destructive raw material identification (RMID) through all types of packaging. Reliable identity verification of peptides, amino acids, protected building blocks, and excipients is a critical step in peptide manufacturing. The Agilent Vaya Raman Raw Material Identity Verification System is specifically designed to identify raw materials directly through non transparent and opaque containers, without opening the package. By leveraging Spatially Offset Raman Spectroscopy (SORS), Vaya minimizes interference from container walls, liners, and fluorescence. This enables fast and reliable identification through typical peptide pharma packaging, including plastic drums, paper and multi layer bags, FIBCs, and amber glass containers. The through container measurement capability eliminates the need for sampling, significantly reducing the risk of cross contamination and protecting operators from hazardous, highly potent, or sterile materials. At the same time, it streamlines workflows by reducing handling steps and operator exposure. Agilent Vaya supports high throughput, GMP compliant raw material testing, accelerates release to manufacturing, and helps ensure a secure, efficient supply of materials for peptide synthesis and downstream processing—from early development to commercial production.

 

12:40 - 13:15 - Talk 4: Advanced Column Solutions to enhance your Peptide Analysis and Purification Workflows

Katrien Sabbe, Agilent Technologies

 

Whether you're optimizing existing methods or developing new ones, this session will equip you with the tools to streamline your peptide characterization and purification. LC analysis of peptides can be challenging due to their sensitivity to metal interactions within chromatographic systems, often leading to poor peak shape and reduced sensitivity. Agilent Altura HPLC columns with Ultra Inert technology overcome these challenges by minimizing metal-analyte interactions. We will illustrate how this innovation enhances resolution, reproducibility, and quantification in reversed phase and HILIC separations of therapeutic peptides such as GLP-1 receptor agonists. Furthermore we will explore preparative techniques and purification workflows, offering tips for achieving high purity and recovery in synthetic peptide purification.

 

BEGIN:VALARM ACTION:DISPLAY TRIGGER:-PT15M DESCRIPTION:Innovations and Emerging Tools in Peptide Science END:VALARM END:VEVENT END:VCALENDAR